Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Iaffaldano

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
International Journal of Molecular Sciences|February 13, 2025
A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current PerspectiveTommaso Guerra, Pietro Iaffaldano
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2024
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggersEmilio Portaccio, Pietro Iaffaldano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 22, 2025
Unraveling X-linked adrenoleukodystrophy in women: a rare case of central nervous system manifestations and implications for screeningChiara Esposto, Pietro Iaffaldano
Nature Reviews. Neurology|February 26, 2021
Assessing long-term effectiveness of MS treatment - a matter of debateMaria Trojano, Pietro Iaffaldano
Current Opinion in Neurology|April 2, 2026
Big data in multiple sclerosisMaria Trojano, Pietro Iaffaldano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2018
Natalizumab reduces serum pro-angiogenic activity in MS patientsPietro Iaffaldano, Domenico Ribatti, Maria Trojano
Expert Review of Neurotherapeutics|November 19, 2011
Treating multiple sclerosis with natalizumabPietro Iaffaldano, Guglielmo Lucchese, Maria Trojano
Journal of Neurology|June 5, 2016
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patientsPietro Iaffaldano, Rosa Gemma Viterbo, Maria Trojano
Clinical and Experimental Medicine|December 26, 2014
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patientsDomenico Ribatti, Pietro Iaffaldano, Christian Marinaccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Dengue fever in a multiple sclerosis patient taking OcrelizumabTommaso Guerra, Luca Bollo, Maria Trojano, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
International Journal of Molecular Sciences|February 13, 2025
A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current PerspectiveTommaso Guerra, Pietro Iaffaldano
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2024
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggersEmilio Portaccio, Pietro Iaffaldano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 22, 2025
Unraveling X-linked adrenoleukodystrophy in women: a rare case of central nervous system manifestations and implications for screeningChiara Esposto, Pietro Iaffaldano
Nature Reviews. Neurology|February 26, 2021
Assessing long-term effectiveness of MS treatment - a matter of debateMaria Trojano, Pietro Iaffaldano
Current Opinion in Neurology|April 2, 2026
Big data in multiple sclerosisMaria Trojano, Pietro Iaffaldano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2018
Natalizumab reduces serum pro-angiogenic activity in MS patientsPietro Iaffaldano, Domenico Ribatti, Maria Trojano
Expert Review of Neurotherapeutics|November 19, 2011
Treating multiple sclerosis with natalizumabPietro Iaffaldano, Guglielmo Lucchese, Maria Trojano
Journal of Neurology|June 5, 2016
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patientsPietro Iaffaldano, Rosa Gemma Viterbo, Maria Trojano
Clinical and Experimental Medicine|December 26, 2014
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patientsDomenico Ribatti, Pietro Iaffaldano, Christian Marinaccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Dengue fever in a multiple sclerosis patient taking OcrelizumabTommaso Guerra, Luca Bollo, Maria Trojano, et al.
Pageof 10